La Sociedad de Leucemia y Linfoma (LLS) y la Sociedad Americana de Hematología (ASH) colaborarán para educar e informar sobre la necesidad de nuevos tratamientos para la leucemia mieloide aguda (AML, por sus siglas en inglés), una de las formas de cáncer más graves, y en la cual no ha habido cambios sustanciales en cuanto a terapias durante más de cuatro décadas/The Leukemia & Lymphoma Society (LLS) and the American Society of Hematology (ASH) are teaming up to raise awareness and provide education about the need for new treatments for acute myeloid leukemia (AML), one of the most deadly blood cancers that has not seen a change in the standard of care for more than 40 years.
AML is a complex group of approximately 20 different types of blood cancers with a very poor survival prognosis. AML impacts approximately 20,000 Americans annually, and causes more than 10,000 deaths in the U.S. each year.
As the world’s largest voluntary health organization dedicated to fighting blood cancers, LLS is leading the charge to change the paradigm of treatment for patients with AML. ASH, the premier medical society dedicated to hematologic malignancies and other diseases of the blood, will assist LLS in its efforts to make both patients and healthcare practitioners aware of the importance and availably of AML clinical trials, a critical step in the development of new treatments.
“LLS exists to find cures and to ensure access to treatments for all blood cancer patients, and both LLS and ASH are dedicated to advancing the understanding, diagnosis and treatment of blood cancers, so our missions are truly aligned,” said Louis J. DeGennaro, PhD, LLS’s president and CEO. “In AML, we face one of the most critical unmet medical needs in cancer and by joining forces we aim to promote greater understanding of and participation in clinical trials to help bring more effective therapies to patients, faster.”
In 2013, LLS launched its Beat AML initiative, bringing together key stakeholders – researchers from multiple institutions, patients, pharmaceutical companies, and physicians – to go on the offensive against AML. The initiative is focused on analyzing the genomic causes of the disease – really a constellation of many subtypes – and then identifying agents with the potential to bring these diseases under control. Ultimately, the goal is to develop more precise, individualized, and effective treatments for AML patients.
LLS invests approximately 26% of its research budget in AML and currently supports 66 academic research projects and five biotechnology partnerships in AML through its strategic Therapy Acceleration Program®.
With its broad access to the medical community, ASH will collaborate with LLS to inform physicians and other healthcare providers about the services LLS offers AML patients and families, particularly through LLS’s Information Resource Center, a toll-free call center staffed with master’s level healthcare professionals armed with the latest information about blood cancers. Among the support services provided by LLS’s information specialists is assistance finding appropriate clinical trials. ASH will disseminate information about LLS’s services through its multiple communications channels and publications, both digital and print, and during its cancer conferences.